The Ochsner CCOP, continuously funded since 1983, is a well-organized, tightly integrated clinical research unit in South Louisiana and Mississippi. During the first four years of the current grant cycle (June 1, 1990 - May 31, 1994), this CCOP has placed 610 patients on cancer treatment protocols and 386 participants on NCI-approved cancer control protocols. While it is recognized that accrual is vital to success, the Ochsner CCOP will emphasize that accrual must be associated with high- quality data. This CCOP will continue regular internal audits and strengthen the stringent data monitoring procedures already in place. The expanding CCOP bibliography reflects the leadership and involvement of Ochsner CCOP investigators and staff in all aspects of research base activities. The major goals for the next grant cycle are: 1) To continue to emphasize minority recruitment to cancer clinical trials. To accomplish this goal, the Ochsner CCOP will work closely with the Ochsner Cancer Institute which has recently been awarded an RO1 Grant to enhance cancer control behaviors in African Americans. 2) To concentrate on specific disease areas (colorectal, breast, pediatric cancers) to enhance accrual by forging relationships with the department of colorectal surgery, and with the Ochsner Breast Center. A combined pediatric program will be established between the Ochsner Clinic and Tulane University Hospital. 3) To make the CCOP cost effective in a managed-care environment by working collaboratively with the Ochsner HMO staff.. The recently established Day Hospital will allow administration of complex investigational therapy on an outpatient basis. 4) To increase participation in laboratory correlative studies by involvement of CCOP pathologists who have expressed a high level of interest in these studies. 5) To enhance participation by participants and investigators in cancer control protocols especially chemoprevention trials. The Ochsner CCOP's stable, long-term investigators and staff are committed to the goals outlined. Experience and a strong track record in clinical research assures continued success.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
2U10CA035272-12
Application #
2088912
Study Section
Special Emphasis Panel (SRC (16))
Project Start
1983-09-01
Project End
2000-05-31
Budget Start
1995-06-19
Budget End
1996-05-31
Support Year
12
Fiscal Year
1995
Total Cost
Indirect Cost
Name
Ochsner Clinic Foundation
Department
Type
DUNS #
City
New Orleans
State
LA
Country
United States
Zip Code
70121
Himelstein, Andrew L; Foster, Jared C; Khatcheressian, James L et al. (2017) Effect of Longer-Interval vs Standard Dosing of Zoledronic Acid on Skeletal Events in Patients With Bone Metastases: A Randomized Clinical Trial. JAMA 317:48-58
Pachman, Deirdre R; Qin, Rui; Seisler, Drew et al. (2016) Comparison of oxaliplatin and paclitaxel-induced neuropathy (Alliance A151505). Support Care Cancer 24:5059-5068
Gonsalves, Wilson I; Mahoney, Michelle R; Sargent, Daniel J et al. (2014) Patient and tumor characteristics and BRAF and KRAS mutations in colon cancer, NCCTG/Alliance N0147. J Natl Cancer Inst 106:
Barton, Debra L; Thanarajasingam, Gita; Sloan, Jeff A et al. (2014) Phase III double-blind, placebo-controlled study of gabapentin for the prevention of delayed chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy, NCCTG N08C3 (Alliance). Cancer 120:3575-83
Leal, Alexis D; Qin, Rui; Atherton, Pamela J et al. (2014) North Central Cancer Treatment Group/Alliance trial N08CA-the use of glutathione for prevention of paclitaxel/carboplatin-induced peripheral neuropathy: a phase 3 randomized, double-blind, placebo-controlled study. Cancer 120:1890-7
Huang, Jocelin; Nair, Suresh G; Mahoney, Michelle R et al. (2014) Comparison of FOLFIRI with or without cetuximab in patients with resected stage III colon cancer; NCCTG (Alliance) intergroup trial N0147. Clin Colorectal Cancer 13:100-9
Province, M A; Goetz, M P; Brauch, H et al. (2014) CYP2D6 genotype and adjuvant tamoxifen: meta-analysis of heterogeneous study populations. Clin Pharmacol Ther 95:216-27
Sticca, Robert P; Alberts, Steven R; Mahoney, Michelle R et al. (2013) Current use and surgical efficacy of laparoscopic colectomy in colon cancer. J Am Coll Surg 217:56-62; discussion 62-3
Barton, Debra L; Burger, Kelli; Novotny, Paul J et al. (2013) The use of Ginkgo biloba for the prevention of chemotherapy-related cognitive dysfunction in women receiving adjuvant treatment for breast cancer, N00C9. Support Care Cancer 21:1185-92
Lavoie Smith, Ellen M; Barton, Debra L; Qin, Rui et al. (2013) Assessing patient-reported peripheral neuropathy: the reliability and validity of the European Organization for Research and Treatment of Cancer QLQ-CIPN20 Questionnaire. Qual Life Res 22:2787-99

Showing the most recent 10 out of 72 publications